| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1986PNAS...83.9129D |
| P356 | DOI | 10.1073/PNAS.83.23.9129 |
| P932 | PMC publication ID | 387088 |
| P698 | PubMed publication ID | 3466178 |
| P5875 | ResearchGate publication ID | 19690517 |
| P50 | author | Robert Weinberg | Q701506 |
| Jeffrey Drebin | Q56230415 | ||
| P2093 | author name string | M I Greene | |
| V C Link | |||
| P2860 | cites work | Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 |
| Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies | Q28282033 | ||
| Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene | Q28286890 | ||
| The v-sis/PDGF-2 transforming gene product localizes to cell membranes but is not a secretory protein | Q33931532 | ||
| Cellular Transforming Genes | Q34253517 | ||
| Cellular oncogenes and retroviruses | Q34256815 | ||
| Regulation of the immune response to tumor antigen | Q36092841 | ||
| A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma | Q36423957 | ||
| Nucleotide sequence of avian sarcoma virus UR2 and comparison of its transforming gene with other members of the tyrosine protein kinase oncogene family | Q36899491 | ||
| Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line | Q36911274 | ||
| Cell surface expression of v-fms-coded glycoproteins is required for transformation | Q36948284 | ||
| Human squamous cell lung cancers express increased epidermal growth factor receptors | Q36993618 | ||
| Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo | Q37348039 | ||
| Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines | Q37578238 | ||
| Study of antibodies against human melanoma produced by somatic cell hybrids | Q37590914 | ||
| Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma | Q37678574 | ||
| Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer | Q41362569 | ||
| Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene | Q42817276 | ||
| Identification and characterization of the avian erythroblastosis virus erbB gene product as a membrane glycoprotein | Q45798962 | ||
| Amplification of a novel v-erbB-related gene in a human mammary carcinoma | Q48375434 | ||
| Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin | Q48536258 | ||
| The action of oncogenes in the cytoplasm and nucleus | Q52457489 | ||
| The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen | Q52827123 | ||
| Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies | Q53436863 | ||
| Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells | Q70044881 | ||
| Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen | Q72072771 | ||
| Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody | Q72483017 | ||
| Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours | Q72522239 | ||
| Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody | Q72657705 | ||
| Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells | Q72912984 | ||
| P4510 | describes a project that uses | monoclonal antibody | Q422248 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 9129-33 | |
| P577 | publication date | 1986-12-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen | |
| P478 | volume | 83 |
| Q42800730 | A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product |
| Q99574593 | A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity |
| Q71803432 | A target for tumour-directed therapy |
| Q52597562 | A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ. |
| Q36607857 | Adaptive Immune Responses and HER2/neu-Positive Breast Cancer |
| Q55481474 | Analysis of c-erbB2 protein content of human glioma cells and tumor tissue. |
| Q73804618 | Anti-P-glycoprotein Antibody C219 Cross-reactivity With c-erbB2 Protein: Diagnostic and Clinical Implications |
| Q41017774 | Antisense Oligonucleotides Specific for the HER2/neu Oncogene Inhibit the Growth of Human Breast Carcinoma Cells That Overexpress HER2/neu |
| Q36755501 | Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene |
| Q40619186 | Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neu in HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway |
| Q38902450 | Applications of genetically encoded photosensitizer miniSOG: from correlative light electron microscopy to immunophotosensitizing. |
| Q41080371 | Binding-induced activation of overexpressed p185HER2 is essential in triggering neuronal differentiation of PC12 cells |
| Q37453793 | Cancer therapeutic antibodies come of age: targeting minimal residual disease |
| Q51838845 | Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). |
| Q37250084 | Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2. |
| Q36113684 | Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors |
| Q34350358 | Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector |
| Q40721158 | Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats |
| Q24683709 | ErbB receptors: from oncogenes to targeted cancer therapies |
| Q91790579 | ErbB-2 signaling in advanced prostate cancer progression and potential therapy |
| Q36946835 | Expression Enhancement in Trastuzumab Therapeutic Monoclonal Antibody Production using Genomic Amplification with Methotrexate |
| Q68298654 | Expression of C-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for C-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma |
| Q35982167 | Expression of c-erbB-2 protein product in bladder cancer |
| Q24538358 | External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator |
| Q33907971 | Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies |
| Q38671576 | Genetic alterations in primary breast cancer |
| Q39047491 | Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro |
| Q38301236 | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer |
| Q34130563 | HER2/neu antisense targeting of human breast carcinoma |
| Q34248406 | HER2: the neu prognostic marker for breast cancer |
| Q47759025 | Human Tumor Growth Suppression by Apoptosis Induced with Anti‐ErbB‐2 Chimeric Monoclonal Antibody |
| Q41710798 | Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors |
| Q61822549 | Immunological prevention of spontaneous tumors: a new prospect? |
| Q36181177 | Immunoscreening protocols for the identification of clinically useful antibodies and antigens |
| Q24651825 | Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases |
| Q45876548 | Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice |
| Q36401520 | Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. |
| Q30951804 | Investigating the substrate specificity of the HER2/Neu tyrosine kinase using peptide libraries |
| Q33958678 | Jeremiah Metzger Lecture. Targeted cancer therapy |
| Q37659437 | Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers |
| Q37856115 | Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? |
| Q37600965 | Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth |
| Q37938041 | Molecules, cancer, and the surgeon. A review of molecular biology and its implications for surgical oncology |
| Q38702679 | Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications |
| Q41687861 | Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors |
| Q51085661 | Optimism after much pessimism: what next? |
| Q33931164 | Overexpression of ErbB2 in cancer and ErbB2-targeting strategies |
| Q44876355 | Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification |
| Q42109603 | Pattern of expression of c-erbB-2 oncoprotein in human fetuses |
| Q37117664 | Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis |
| Q38099304 | Personalizing Oncology: Perspectives and Prospects |
| Q50781453 | Photodynamic destruction of lysosomes mediated by Nile blue photosensitizers |
| Q71803451 | Prevention of breast tumour development in vivo by downregulation of the p185neureceptor |
| Q33611354 | Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor |
| Q24646978 | Quercetin-induced ubiquitination and down-regulation of Her-2/neu |
| Q41808881 | Quit your YAPing: a new target for cancer therapy |
| Q55476205 | Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. |
| Q38195895 | Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies |
| Q38047648 | Reversion of the ErbB malignant phenotype and the DNA damage response. |
| Q37148681 | Structure based antibody-like peptidomimetics |
| Q35176356 | Structure-based approaches to inhibition of erbB receptors with peptide mimetics |
| Q37912948 | Studies of human breast cancer metastasis using nude mice |
| Q54081688 | Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents |
| Q34016364 | Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model |
| Q34424285 | Testing for HER2 in Breast Cancer: A Continuing Evolution |
| Q34293543 | The EGF receptor family as targets for cancer therapy |
| Q33855994 | The ErbB receptors as targets for breast cancer therapy |
| Q42815809 | The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. |
| Q38802932 | The assessment of HER2 status in breast cancer: the past, the present, and the future |
| Q63446373 | The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines |
| Q36900099 | The legacy of the Philadelphia chromosome |
| Q40529932 | The neu-protein and breast cancer |
| Q37326072 | The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies |
| Q38648690 | Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. |
| Q33959344 | Type I receptor tyrosine kinases as targets for therapy in breast cancer |
| Q36466645 | c-erbB-2 expression in benign and malignant breast disease |
| Q35983286 | c-erbB-2 oncoprotein expression in primary and advanced breast cancer |
| Q36080272 | erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification |
| Q36778011 | scFv-Based “Grababody” as a General Strategy to Improve Recruitment of Immune Effector Cells to Antibody-Targeted Tumors |
Search more.